Therapeutic injection of parp inhibitor ino-1001 preserves cardiac function in porcine myocardial ischemia and reperfusion without reducing infarct size

Shock

Volumn 33, Issue 5, 2010, Pages 507-512

  Roesner, Jan P ^a   Mersmann, Jan ^b   Bergt, Stefan ^a   Bohnenberg, Karl ^a   Barthuber, Carmen ^c   Szabo, Csaba ^d   Nöldge Schomburg, Gabriele E F ^a   Zacharowski, Kai ^b  

^a ROSTOCK UNIVERSITY MEDICAL CENTER   (Germany)

^b UNIVERSITY HOSPITAL FRANKFURT   (Germany)

^c UNIVERSITY HOSPITAL DÜSSELDORF   (Germany)

^d University of Texas Medical Branch School of Medicine   (United States)

Author keywords

INO 1001; Ischemic preconditioning; Myocardial ischemia; PARP; Reperfusion injury

Indexed keywords

BIOLOGICAL MARKER; CREATINE KINASE; EVANS BLUE; GLUCOSE; INO 1001; LACTATE DEHYDROGENASE; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE INHIBITOR; TRIPHENYLTETRAZOLIUM; TROPONIN T; CARDIOTONIC AGENT; INDOLE DERIVATIVE; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTERY CATHETER; ARTICLE; BLOOD SAMPLING; CLINICAL ASSESSMENT; CONTROLLED STUDY; DRUG HALF LIFE; DRUG INHIBITION; FEMORAL ARTERY; HEART FUNCTION; HEART INDEX; HEART INFARCTION; HEART INFARCTION SIZE; HEART MUSCLE INJURY; HEART MUSCLE ISCHEMIA; HEART MUSCLE REPERFUSION; HEART PROTECTION; HEART STROKE VOLUME; INJECTION; ISCHEMIC PRECONDITIONING; LANDRACE; LEFT ANTERIOR DESCENDING CORONARY ARTERY; MALE; NONHUMAN; OXYGEN SATURATION; PULMONARY ARTERY; STAINING; SWINE; VENOUS OXYGEN TENSION; ANIMAL; ANTAGONISTS AND INHIBITORS; DRUG EFFECTS; HEART INFARCTION PREVENTION; HEMODYNAMICS; MYOCARDIAL INFARCTION; MYOCARDIAL REPERFUSION INJURY; PATHOLOGY;

ANIMALS; CARDIOTONIC AGENTS; HEMODYNAMICS; INDOLES; ISCHEMIC PRECONDITIONING, MYOCARDIAL; MALE; MYOCARDIAL INFARCTION; MYOCARDIAL REPERFUSION INJURY; POLY(ADP-RIBOSE) POLYMERASES; SWINE;

EID: 77951436549     PISSN: 10732322     EISSN: None     Source Type: Journal    
DOI: 10.1097/SHK.0b013e3181c4fb08     Document Type: Article

References (32)

1. Yellon DM, Hausenloy DJ: Mechanisms of disease: myocardial reperfusion injury. N Engl J Med 357:1121-1135, 2007.
2. Thiemermann C, Bowes J, Myint FP, Vane JR: Inhibition of the activity of poly(ADP ribose) synthetase reduces ischemia-reperfusion injury in the heart and skeletal muscle. Proc Natl Acad Sci USA 94:679-683, 1997. (Pubitemid 27053693)
3. Szabo G, Zingarelli B, O'Connor M, Salzman AL: DNA strand breakage, activation of poly (ADP-ribose) synthetase, and cellular energy depletion are involved in the cytotoxicity of macrophages and smooth muscle cells exposed to peroxynitrite. Proc Natl Acad Sci 93:1753-1758, 1996. (Pubitemid 26079829)
4. Schreiber V, Dantzer F, Ame JC, de Murcia G: Poly(ADP-ribose): novel functions for an old molecule. Nat Rev Mol Cell Biol 7:517-528, 2006. (Pubitemid 44036457)
5. Pacher P, Szabo C: Role of the peroxynitrite-poly(ADP-ribose) polymerase pathway in human disease. Am J Pathol 173:2-13, 2008. (Pubitemid 351947950)
6. McCourtie AS, Farivar AS, Woolley SM, Merry HE, Wolf PS, Szabo C, Mulligan MS: Poly (ADP) ribose synthetase inhibition in alveolar macrophages undergoing hypoxia and reoxygenation. Exp Mol Pathol 84:141-144, 2008.
7. Murthy KG, Xiao CY, Mabley JG, Chen M, Szabo C: Activation of poly (ADP-ribose) polymerase in circulating leukocytes during myocardial infarction. Shock 21:230-234, 2004.
8. Liaudet L, Szabo E, Timashpolsky L, Virag L, Cziraki A, Szabo C: Suppression of poly (ADP-ribose) polymerase activation by 3-aminobenzamide in a rat model of myocardial infarction: long-term morphological and functional consequences. Br J Pharmacol 133:1424-1430, 2001. (Pubitemid 32783505)
9. Zingarelli B, Salzman AL, Szabo C: Genetic disruption of poly (ADP-ribose) synthetase inhibits the expression of P-selectin and intercellular adhesion molecule-1 in myocardial ischemia/reperfusion injury. Circ Res 83:85-94, 1998. (Pubitemid 28322102)
10. Kovacs K, Hanto K, Bognar Z, Tapodi A, Bognar E, Kiss GN, Szabo A, Rappai G, Kiss T, Sumegi B, et al.: Prevalent role of Akt and ERK activation in cardioprotective effect of Ca(2+) channel-and beta-adrenergic receptor blockers. Mol Cell Biochem 321:155-164, 2009.
11. Song ZF, Ji XP, Li XX, Wang SJ, Wang SH, Zhang Y: Inhibition of the activity of poly (ADP-ribose) polymerase reduces heart ischaemia/reperfusion injury via suppressing JNK-mediated AIF translocation. J Cell Mol Med 12:1220-1228, 2008.
12. del Rio CL, McConnell PI, Clymer BD, Dzwonczyk R, Michler RE, Billman GE, Howie MB: Early time course of myocardial electrical impedance during acute coronary artery occlusion in pigs, dogs, and humans. J Appl Physiol 99:1576-1581, 2005. (Pubitemid 43014369)
13. Maxwell MP, Hearse DJ, Yellon DM: Species variation in the coronary collateral circulation during regional myocardial ischaemia: a critical determinant of the rate of evolution and extent of myocardial infarction. Cardiovasc Res 21:737-746, 1987.
14. Roesner JP, Petzelbauer P, Koch A, Mersmann J, Zacharowski PA, Boehm O, Reingruber S, Pasteiner W, Mascher D, Wolzt M, et al.: The fibrin-derived peptide Bbeta15-42 is cardioprotective in a pig model of myocardial ischemia-reperfusion injury. Crit Care Med 35:1730-1735, 2007. (Pubitemid 46985877)
15. Morrow DA, Brickman CM, Murphy SA, Baran K, Krakover R, Dauerman H, Kumar S, Slomowitz N, Grip L, McCabe CH, et al.: A randomized, placebo-controlled trial to evaluate the tolerability, safety, pharmacokinetics, and pharmacodynamics of a potent inhibitor of poly(ADP-ribose) polymerase (INO-1001) in patients with ST-elevation myocardial infarction undergoing primary percutaneous coronary intervention: results of the TIMI 37 trial. J Thromb Thrombolysis 27:359-364, 2009.
16. Faro R, Toyoda Y, McCully JD, Jagtap P, Szabo E, Virag L, Bianchi C, Levitsky S, Szabo C, Sellke FW: Myocardial protection by PJ34, a novel potent poly (ADP-ribose) synthetase inhibitor. Ann Thorac Surg 73:575-581, 2002. (Pubitemid 34117412)
17. Bowes J, Ruetten H, Martorana PA, Stockhausen H, Thiemermann C: Reduction of myocardial reperfusion injury by an inhibitor of poly (ADP-ribose) synthetase in the pig. Eur J Pharmacol 359:143-150, 1998. (Pubitemid 28513010)
18. Yuan M, Siegel C, Zeng Z, Li J, Liu F, McCullough LD: Sex differences in the response to activation of the poly (ADP-ribose) polymerase pathway after experimental stroke. Exp Neurol 217:210-218, 2009.
19. Oyama J, Blais C Jr, Liu X, Pu M, Kobzik L, Kelly RA, Bourcier T: Reduced myocardial ischemia-reperfusion injury in toll-like receptor 4-deficient mice. Circulation 109:784-789, 2004. (Pubitemid 38222900)
20. Kim SC, Ghanem A, Stapel H, Tiemann K, Knuefermann P, Hoeft A, Meyer R, Grohe C, Knowlton AA, Baumgarten G: Toll-like receptor 4 deficiency: smaller infarcts, but no gain in function. BMC Physiol 7:5, 2007. (Pubitemid 47206831)
21. Giugliano GR, Giugliano RP, Gibson CM, Kuntz RE: Meta-analysis of corti-costeroid treatment in acute myocardial infarction. Am J Cardiol 91:1055-1059, 2003. (Pubitemid 36514919)
22. Bolli R, Becker L, Gross G, Mentzer R Jr, Balshaw D, Lathrop DA: Myo-cardial protection at a crossroads: the need for translation into clinical therapy. Circ Res 95:125-134, 2004. (Pubitemid 38988678)
23. Hauser B, Groger M, Ehrmann U, Albicini M, Bruckner UB, Schelzig H, Venkatesh B, Li H, Szabo C, Speit G, et al.: The PARP-1 inhibitor INO-1001 facilitates hemodynamic stabilization without affecting DNA repair in porcine thoracic aortic cross-clamping-induced ischemia/reperfusion. Shock 25: 633-640, 2006. (Pubitemid 44297025)
24. Khan TA, Ruel M, Bianchi C, Voisine P, Komjbti K, Szabo C, Sellke FW: Poly(ADP-ribose) polymerase inhibition improves postischemic myocardial function after cardioplegia-cardiopulmonary bypass. J Am Coll Surg 197: 270-277, 2003. (Pubitemid 36927390)
25. Maier C, Scheuerle A, Hauser B, Schelzig H, Szabo C, Radermacher P, Kick J: The selective poly(ADP)ribose-polymerase 1 inhibitor INO1001 reduces spinal cord injury during porcine aortic cross-clamping-induced ischemia/reperfusion injury. Intensive Care Med 33:845-850, 2007. (Pubitemid 46675322)
26. Iványi Z, Hauser B, Pittner A, Asfar P, Vassilev D, Nalos M, Altherr J, Bruckner UB, Szabo C, Radermacher P, et al.: Systemic and hepatosplanchnic hemodynamic and metabolic effects of the PARP inhibitor PJ34 during hyper-dynamic porcine endotoxemia. Shock 19:415-421, 2003. (Pubitemid 44305166)
27. Szabo G, Soos P, Heger U, Flechtenmacher C, Bahrle S, Zsengeller Z, Szabo C, Hagl S: Poly(ADP-ribose) polymerase inhibition attenuates biventricular reper-fusion injury after orthotopic heart transplantation. Eur J Cardiothorac Surg 27: 226-234, 2005. (Pubitemid 40193131)
28. Hausenloy DJ, Yellon DM: Remote ischaemic preconditioning: underlying mechanisms and clinical application. Cardiovasc Res 79:377-386, 2008.
29. Pacher P, Vaslin A, Benko R, Mabley JG, Liaudet L, Hasko G, Marton A, Batkai S, Kollai M, Szabo C: A new, potent poly(ADP-ribose) polymerase inhibitor improves cardiac and vascular dysfunction associated with advanced aging. J Pharmacol Exp Ther 311:485-491, 2004. (Pubitemid 39391532)
30. Radovits T, Zotkina J, Lin LN, Bomicke T, Arif R, Gero D, Horvath EM, Karck M, Szabo C, Szabo G: Poly(ADP-ribose) polymerase inhibition improves endothelial dysfunction induced by hypochlorite. Exp Biol Med 232: 1204-1212, 2007. (Pubitemid 47503061)
31. Xiao CY, Chen M, Zsengeller Z, Li H, Kiss L, Kollai M, Szabo C: Poly(ADP-ribose) polymerase promotes cardiac remodeling, contractile failure, and translocation of apoptosis-inducing factor in a murine experimental model of aortic banding and heart failure. J Pharmacol Exp Ther 312:891-898, 2005. (Pubitemid 40293746)
32. Beller CJ, Radovits T, Kosse J, Gerö D, Szabo C, Szabo G: Activation of the peroxynitrite-poly(adenosine diphosphateYribose) polymerase pathway during neointima proliferation: a new target to prevent restenosis after endarterec-tomy. J Vasc Surg 43:824-830, 2006.